Physician profile
Aaron C Kopp
NPI 1144507583
$3,759.59
in general payments reported to CMS, 2019-2025
22 companies · $508 in 2025
The $508 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $212 · 2022: $350 · 2023: $1,557 · 2024: $1,133 · 2025: $508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,197.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,194.03 | 2021-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $468.45 | 2022-2025 | Farxiga, Wainua, Brilinta |
| Novartis Pharmaceuticals Corporation | $302.96 | 2022-2024 | |
| Atricure, INC. | $194.10 | 2023-2024 | |
| Impulse Dynamics (USA) INC. | $194.08 | 2023-2024 | Optimizer, Optimizer |
| Pfizer INC. | $189.63 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $185.67 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $132.40 | 2022-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $122.44 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.03 | 2022-2025 | Jardiance |
| Abiomed | $103.93 | 2025 | |
| Scpharmaceuticals INC. | $98.37 | 2023-2024 | |
| Philips North America LLC | $81.42 | 2023-2025 | Extended Holter |
| Merck Sharp & Dohme LLC | $78.50 | 2023 | Verquvo, Belsomra |
| Kestra Medical Technology Services, INC. | $68.41 | 2023 | Assure Wcd |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $54.86 | 2023-2024 | Nexletol |
| Lexicon Pharmaceuticals, INC. | $51.11 | 2023 | Inpefa |
| Boston Scientific Corporation | $37.01 | 2022-2023 | Bodyguardian |
| Abbott Laboratories | $36.07 | 2022 | |
| Bridgebio Pharma, INC. | $22.65 | 2025 | Attruby |
| Amgen INC. | $16.46 | 2023 | Repatha |
| Alnylam Pharmaceuticals INC. | $16.01 | 2025 | Amvuttra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Kopp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.